The US market has been relatively stable over the past week, yet there’s been a noteworthy 10.0% growth over the last year, with projections suggesting a 15% yearly increase in revenue. Given this backdrop, finding technology stocks with high growth potential requires a focus on companies that exhibit strong revenue growth and innovation in alignment with these positive earnings forecasts.
| name | Revenue growth | Revenue growth | Growth rate |
|---|---|---|---|
| Super Microcomputer | 26.38% | 39.09% | ★★★★★ |
| Mereo Biopharma Group | 53.63% | 66.57% | ★★★★★ |
| adelyx | 21.03% | 60.42% | ★★★★★ |
| TG Therapeutics | 26.46% | 38.75% | ★★★★★ |
| Avita Medical | 27.42% | 61.05% | ★★★★★ |
| Blueprints Pharmaceuticals | 21.12% | 60.77% | ★★★★★ |
| Alnylam Pharmaceuticals | 23.63% | 60.61% | ★★★★★ |
| Alkami Technology | 20.53% | 76.67% | ★★★★★ |
| Ascendis Pharma | 35.07% | 59.92% | ★★★★★ |
| Lumentum Holdings | 22.99% | 103.97% | ★★★★★ |
Now, let’s explore some notable selections from these companies.
Simply put, wall ST growth rate: ★★★★☆☆
Overview: Akebia Therapeutics, Inc. is a biopharmaceutical firm focused on developing drugs for kidney disease, boasting a market cap of $966.5 million.
Operation: The company is centered on creating and marketing kidney treatments, generating $184.91 million from innovative products.
Currently, Akebia is in a transformational phase, having recently received FDA approval for VAFSEO and reported positive outcomes from phase 3 trials. Revenues jumped to $57.34 million from $32.61 million in the first quarter of 2025 compared to the previous year, suggesting a solid growth path. It’s expected that annual revenue growth will reach 19.8%, exceeding the broader US market’s anticipated 8.7%. Looking ahead, revenue is projected to grow at an impressive annual rate of 63.52%, indicating a potential path to profitability within three years, especially as the company adapts to competition in the chronic kidney disease treatment space.
Simply put, wall ST growth rate: ★★★★★
Overview: TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company committed to the acquisition and development of treatments for B-cell-mediated diseases, valued at $5.25 billion.
Operation: The company focuses on treatments for B-cell disorders, generating revenue primarily from biotechnology, totaling $38.639 million.
TG Therapeutics displays a promising growth trajectory, with revenues increasing by 26.5% and profits expected to rise 38.8% annually, clearly outpacing the national average of 14.6%. This development is backed by significant R&D expenditures fostering innovation in multiple sclerosis treatments. Positive data from recent presentations and increased revenue expectations for Briumvi® are noteworthy. The company’s strategy of expanding its product offerings aligns with broader trends in professional healthcare solutions, positioning TG Therapeutics to seize new opportunities as the biotech landscape continues to evolve.
Simply put, wall ST growth rate: ★★★★★☆
Overview: Arcutis Biotherapeutics, Inc. specializes in developing treatments for dermatological disorders and has a market cap of around $1.65 billion.
Operation: The firm generates its income mainly from dermatology treatments, pulling in $22.282 million.
Arcutis has made strides in dermatology, particularly with recent advancements in FDA approvals and clinical trials. The company emphasizes the use of phosphodiesterase-4 (PDE4) inhibitors for conditions like psoriasis and atopic dermatitis. Recent data from a study showcased the effectiveness of Zoryve Cream, positively impacting chronic skin condition management. With revenue increasing from $49.57 million to $65.85 million year-over-year and decreased net losses, Arcutis is set to leverage R&D innovations for sustainable growth, especially as they anticipate future market expansions post-PDUFA.
